• Valemetostat (DS-3201): Advancing Epigenetic Oncology

  2026-07-03

  This thought-leadership article explores the translational impact of Valemetostat (DS-3201), a selective dual EZH1/EZH2 inhibitor, within the evolving landscape of epigenetic cancer therapy. Through mechanistic insights, workflow guidance, and evidence-based clinical context, we empower translational researchers to bridge molecular understanding with patient-centric innovations in relapsed/refractory lymphoma.

• Glucocorticoid Receptor-Mediated CYP Suppression in Hippocam

  2026-07-03

  This study reveals that pregnenolone 16α-carbonitrile (PCN) suppresses hippocampal cytochrome P450 expression and mitigates phenytoin-induced neurotoxicity through a glucocorticoid receptor-dependent, PXR-independent pathway. These findings clarify nuclear receptor cross-talk in the brain and suggest new strategies to minimize neurological side effects of antiepileptic drugs.

• USP36-Snail1 Axis Drives Ribosome Biogenesis Under Ribotoxic

  2026-07-02

  This study reveals that USP36 stabilizes nucleolar Snail1, promoting ribosome biogenesis and solid tumor survival during ribotoxic stress. These findings clarify why ribosome-targeting agents like homoharringtonine are less effective in solid tumors and suggest combinatorial strategies to overcome resistance.

• Optimizing Cancer Epigenetics with EPZ-6438: EZH2 Inhibitor

  2026-07-02

  EPZ-6438, a potent EZH2 inhibitor from APExBIO, is redefining experimental strategies in epigenetic cancer research by enabling precise modulation of PRC2 activity. This guide unpacks optimized protocols, troubleshooting tactics, and translational insights for leveraging EPZ-6438 in HPV-associated and rare tumor models.

• CHIR-99021 (CT99021): Elevating Pluripotency and Directed Di

  2026-07-01

  CHIR-99021 (CT99021) stands out as a potent, selective GSK-3 inhibitor, enabling precise control of embryonic stem cell fate and robust neuronal differentiation. Here, we detail actionable workflows, highlight cross-domain findings, and deliver troubleshooting strategies to maximize experimental consistency in stem cell and neuron-based models.

• Thioguanine: Mechanistic Insights and Translational Strategi

  2026-07-01

  Explore how 6-thioguanine’s dual targeting of DNMT1 and HGPRT unlocks new frontiers in cancer, antiviral, and inflammatory disease research. This thought-leadership piece bridges mechanistic understanding with actionable guidance for translational researchers, contextualizing key findings from relapsed ALL drug resistance profiling and the latest workflow advances, while positioning APExBIO’s high-purity Thioguanine as a platform for innovation.

• Targeting Metabolic Dependencies in IDH2-Mutant AML with AG-

  2026-06-30

  This thought-leadership article dissects the mechanistic underpinnings and translational opportunities in targeting mutant IDH2-driven metabolic vulnerabilities in acute myeloid leukemia (AML). It integrates the latest insights into CD44-mediated metabolic rewiring, experimental advances using AG-221 (Enasidenib), and strategic guidance for translational researchers aiming to overcome resistance in hematologic malignancies with IDH2 mutations.

• 5-Azacytidine: Epigenetic Modulation for Translational Impac

  2026-06-30

  This thought-leadership article explores how 5-Azacytidine (5-AzaC) is transforming epigenetic research and translational oncology. Drawing on recent mechanistic breakthroughs—such as UHRF1-mediated methylation in senile osteoporosis and gene reactivation in cancer—this article provides mechanistic insights, validated protocols, and strategic guidance for researchers seeking to harness DNA demethylation agents in disease models. It further differentiates itself by projecting the future role of 5-Azacytidine beyond conventional cancer paradigms, highlighting novel workflow opportunities and experimental frontiers.

• Berberine Hydrochloride: Applied Protocols for Gut-Bone Axis

  2026-06-29

  Berberine hydrochloride unlocks new experimental pathways for osteoimmune and metabolic research by bridging the gut-bone axis with metabolic regulation. This article details actionable workflows, troubleshooting tips, and the latest innovations stemming from tuft cell expansion, offering researchers a protocol-ready roadmap for translational studies.

• (-)-JQ1: Beyond Control—A Molecular Lens for BET Inhibition

  2026-06-29

  Explore the advanced role of (-)-JQ1 as a stereoisomer and molecular control in epigenetics research. This article uncovers new assay insights and strategic considerations for cancer biology, moving beyond standard protocols for BET bromodomain inhibition.

• LMO2-LDB1 Complex Drives AML Progression: Mechanisms and Imp

  2026-06-28

  This article examines how the interaction between LMO2 and LDB1 promotes acute myeloid leukemia (AML) development, based on new mechanistic findings. The study demonstrates that the LMO2/LDB1 complex is essential for AML cell proliferation and survival, with implications for targeted epigenetic and transcriptional therapies.

• 3-Deazaneplanocin (DZNep): Precision Epigenetic Modulation i

  2026-06-27

  3-Deazaneplanocin (DZNep) stands at the forefront of translational oncology as a dual S-adenosylhomocysteine hydrolase and EZH2 inhibitor, uniquely enabling apoptosis induction and cancer stem cell targeting. This article delivers a practical guide to experimental design, troubleshooting, and protocol refinement, highlighting DZNep's distinct value for epigenetic modulation and tumor heterogeneity research.

• LMO2-LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-06-26

  This article examines how the LMO2-LDB1 transcription complex fuels the proliferation and survival of acute myeloid leukemia (AML) cells, as revealed by Lu et al. The findings identify the LMO2/LDB1 interaction as a potential therapeutic target, with implications for future precision interventions in hematologic malignancies.

• Letrozole: Optimizing Non-Steroidal Aromatase Inhibitor Work

  2026-06-26

  Letrozole stands out as a non-steroidal aromatase inhibitor with precision-targeted action for estrogen modulation in breast cancer research. This guide delivers practical protocol enhancements, troubleshooting guidance, and actionable insights for leveraging Letrozole’s unique molecular features in translational and synaptic biology assays.

• WM-8014: Precision KAT6A Inhibitor for Cancer Biology Workfl

  2026-06-25

  WM-8014 stands out as a highly selective KAT6A inhibitor, enabling robust oncogene-induced senescence and cell cycle arrest assays without confounding cytotoxicity. This article delivers actionable protocols, advanced applications, and troubleshooting strategies for leveraging WM-8014 in next-generation epigenetic and cancer biology research.

11559 records 1/771 page Next 12345 下5页 Last page